Drake A. Russell
A5073845774- Epigenetics and DNA Methylation
- Cancer-related gene regulation
- Histone Deacetylase Inhibitors Research
- Pharmacogenetics and Drug Metabolism
- Cancer Treatment and Pharmacology
- Alcohol Consumption and Health Effects
- Chemical Synthesis and Reactions
- Amino Acid Enzymes and Metabolism
- Adolescent and Pediatric Healthcare
- RNA modifications and cancer
- Bipolar Disorder and Treatment
- Diet, Metabolism, and Disease
- Acute Lymphoblastic Leukemia research
- Metabolomics and Mass Spectrometry Studies
- Lipid metabolism and biosynthesis
- Sulfur Compounds in Biology
- Sulfur-Based Synthesis Techniques
- Drug Transport and Resistance Mechanisms
University of Washington
2020-2024
Abstract Methylation of alkyl thiols is a biotransformation pathway designed to reduce thiol reactivity and potential toxicity, yet the gene protein responsible for human methyltransferase (TMT) activity remain unknown. Here we demonstrate with range experimental approaches using cell lines, in vitro systems, recombinantly expressed enzyme, that methyltransferase-like 7B (METTL7B) catalyzes transfer methyl group from S- adenosyl- l -methionine (AdoMet) hydrogen sulfide (H 2 S) other...
-methylation of drugs containing thiol-moieties often alters their activity and results in detoxification. Historically, scientists attributed methylation exogenous aliphatic phenolic thiols to a putative
Abstract Histone deacetylase inhibitors (HDACi) are part of a growing class epigenetic therapies used for the treatment cancer. Although HDACis effective in T-cell lymphomas, solid tumors with this drugs has not been successful. Overexpression multidrug resistance protein P-glycoprotein (P-gp), encoded by ABCB1, is known to confer HDACi romidepsin vitro, yet increased ABCB1 expression associated patients, suggesting that other mechanisms arise clinic. To identify alternative romidepsin, we...
Ancestral sequence reconstruction can be used to obtain highly thermostable catalysts of fatty acid hydroxylation.
ABSTRACT Histone deacetylase inhibitors (HDACis) are part of a growing class epigenetic therapies used for the treatment cancer. While elevated levels efflux pump P-gp associated with in vitro resistance to romidepsin, this mechanism does not translate clinic. We developed romidepsin-resistant cell line independent function that acts upstream deacetylation process. found expression methyltransferase METTL7A is necessary resistance, and naïve cells can drive thiol-containing HDACis....
<p>Supplemental Table S8 contains information about METTL7A and METTL7B in T-cell lymphoma tissue microarray samples</p>
<p>Supplemental Table S2 contains information about the cross-resistance profile of MCF7 DpVp300 cells for multiple drugs</p>
<p>Figure S2 contains cell cycle analysis and cytotoxicity data for MCF7 DpVp300 cells showing they are resistant to romidepsin do not overexpress P-gp</p>
<p>Figure S1 contains chemical structures of select HDAC inhibitors</p>
<p>Supplemental Table S8 contains information about METTL7A and METTL7B in T-cell lymphoma tissue microarray samples</p>
<p>Supplemental Table S7 contains information about the normal tissue expression of METTL7A and METTL7B</p>
<p>Figure S3 contains gene ontology analysis, motif and nucleosome density from the RNA-seq ATAC-seq data.</p>
<p>Figure S4 contains cytotoxicity assay and immunoblot data from the MCF7 DpVp300 cell lines showing that expression of METTL7A confers resistance.</p>
<p>Figure S1 contains chemical structures of select HDAC inhibitors</p>
<p>Supplemental Table S1 contains information about the chemical structures of HDACi</p>
<p>Figure S2 contains cell cycle analysis and cytotoxicity data for MCF7 DpVp300 cells showing they are resistant to romidepsin do not overexpress P-gp</p>
<div>Abstract<p>Histone deacetylase inhibitors (HDACi) are part of a growing class epigenetic therapies used for the treatment cancer. Although HDACis effective in T-cell lymphomas, solid tumors with this drugs has not been successful. Overexpression multidrug resistance protein P-glycoprotein (P-gp), encoded by <i>ABCB1</i>, is known to confer HDACi romidepsin <i>in vitro</i>, yet increased <i>ABCB1</i> expression associated patients,...
<div>Abstract<p>Histone deacetylase inhibitors (HDACi) are part of a growing class epigenetic therapies used for the treatment cancer. Although HDACis effective in T-cell lymphomas, solid tumors with this drugs has not been successful. Overexpression multidrug resistance protein P-glycoprotein (P-gp), encoded by <i>ABCB1</i>, is known to confer HDACi romidepsin <i>in vitro</i>, yet increased <i>ABCB1</i> expression associated patients,...
<p>Figure S6 contains cell cycle analysis of cells overexpressing METTL7A.</p>
<p>Figure S4 contains cytotoxicity assay and immunoblot data from the MCF7 DpVp300 cell lines showing that expression of METTL7A confers resistance.</p>
<p>Figure S3 contains gene ontology analysis, motif and nucleosome density from the RNA-seq ATAC-seq data.</p>
<p>Supplemental Table S3 contains information from high-throughput sequencing</p>
<p>Figure S5 contains cycle analysis of MCF7 DpVp300 cells following knockdown METTL7A.</p>
<p>Supplemental Table S1 contains information about the chemical structures of HDACi</p>